Bristol Myers Squibb was among the investors in a series B round announced alongside a collaboration with the small molecule drug developer.

US-based small molecule therapeutics developer Octant Bio has secured $80m in a series B round that included Bristol Myers Squibb (BMS), the pharmaceutical firm with which it recently struck a partnership. Life sciences investment firm Catalio Capital Management led the round, which also featured boutique investment bank Allen & Company and venture capital firms 50…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.

Robert Lavine

Robert Lavine is special features editor for Global Venturing.